These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 15172086)

  • 81. Gonadotropin-releasing hormone agonist and add-back therapy: what do the data show?
    Surrey ES
    Curr Opin Obstet Gynecol; 2010 Aug; 22(4):283-8. PubMed ID: 20498596
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Use of a gonadotropin-releasing hormone agonist in the evaluation of postmenopausal virilization due to ovarian hyperthecosis. A case report.
    Koroscil TM; Harter SB; Ouweleen J; Blauer KL
    J Reprod Med; 1996 Apr; 41(4):259-62. PubMed ID: 8728079
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Low-dose tibolone (1.25 mg/d) does not affect muscle strength in older women.
    Ribom EL; Svensson P; van Os S; Larsson M; Naessen T
    Menopause; 2011 Feb; 18(2):194-7. PubMed ID: 20689464
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Use of leuprolide acetate plus tibolone in the treatment of severe premenstrual syndrome.
    Di Carlo C; Palomba S; Tommaselli GA; Guida M; Di Spiezio Sardo A; Nappi C
    Fertil Steril; 2001 Feb; 75(2):380-4. PubMed ID: 11172843
    [TBL] [Abstract][Full Text] [Related]  

  • 85. [Conservative therapeutic possibilities in glandular or adenomatous endometrium hyperplasia].
    Schindler AE
    Zentralbl Gynakol; 1996; 118(6):359-64. PubMed ID: 8768014
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Administration of tibolone decreases 24 h heart rate but not blood pressure of post-menopausal women.
    Cagnacci A; Baldassari F; Arangino S; Alessandrini C; Volpe A
    Maturitas; 2004 Jun; 48(2):155-60. PubMed ID: 15172090
    [TBL] [Abstract][Full Text] [Related]  

  • 87. A prospective, single-centre, single-arm, open label study of the long term use of a gonadotropin releasing hormone agonist (Triptorelin SR, 11.25 mg) in combination with Tibolone add-back therapy in the management of chronic cyclical pelvic pain.
    Alshehre SM; Duffy S; Jones G; Ledger WL; Metwally M
    Reprod Biol Endocrinol; 2020 Apr; 18(1):28. PubMed ID: 32290838
    [TBL] [Abstract][Full Text] [Related]  

  • 88. [Effect of gestagen therapy on clinical and biochemical parameters in patients with atypical endometrial hyperplasia].
    Makarov OV; Sergeev PV; Sviridov NK; Kareva EN; Isaeva EG; Mgdesian KK; Kirpichnikova NV
    Vopr Onkol; 2000; 46(5):570-3. PubMed ID: 11202189
    [TBL] [Abstract][Full Text] [Related]  

  • 89. [Use of a GnRH analogue (leuprorelin) in the therapy of endometriosis].
    Grio R; Geranio R; Porpiglia M; Leidi L; Piacentino R
    Minerva Ginecol; 1997 Sep; 49(9):417-9. PubMed ID: 9446077
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Tibolone vaginal versus per os administration in the management of post-menopausal symptoms.
    Zervoudis S; Iatrakis G; Peitsidis P; Tsikouras P; Galazios G; Liberis V; Navrozoglou I; Ceauşu I; Badiu C
    Rev Med Chir Soc Med Nat Iasi; 2009; 113(2):471-7. PubMed ID: 21491823
    [TBL] [Abstract][Full Text] [Related]  

  • 91. [Treatment of endometrial hyperplasia with Goserelin depot, an LH-RH analog].
    Pozzi M; Castagnola D; Cherubini F
    Minerva Ginecol; 1993 May; 45(5):251-4. PubMed ID: 8351064
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Effect of gonadotropin-releasing hormone hypogonadism on insulin action as assessed by hyperglycemic clamp studies in men.
    Chauhan S; Collins K; Kruger M; Diamond MP
    Fertil Steril; 2004 Apr; 81(4):1092-8. PubMed ID: 15066469
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Regulation of dosage of conjugated equine estrogen is useful for add-back therapy.
    Hoshimoto K; Hayashi M; Ohkura T
    J Med; 2000; 31(3-4):167-75. PubMed ID: 11280448
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Comparison of the efficacy of three progestins in the treatment of simple endometrial hyperplasia without atypia.
    Ozdegirmenci O; Kayikcioglu F; Bozkurt U; Akgul MA; Haberal A
    Gynecol Obstet Invest; 2011; 72(1):10-4. PubMed ID: 21266792
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Short-term administration of tibolone plus GnRH analog before laparoscopic myomectomy.
    Palomba S; Morelli M; Noia R; Santagata M; Oliverio A; Sena T; Zullo F; Mastrantonio P
    J Am Assoc Gynecol Laparosc; 2002 May; 9(2):170-4. PubMed ID: 11960042
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Effects of menopause and tibolone on different cardiovascular biomarkers in healthy women.
    Vassalle C; Cicinelli E; Lello S; Mercuri A; Battaglia D; Maffei S
    Gynecol Endocrinol; 2011 Mar; 27(3):163-9. PubMed ID: 20500110
    [TBL] [Abstract][Full Text] [Related]  

  • 97. The effect of add-back treatment with tibolone (Livial) on patients treated with the gonadotropin-releasing hormone agonist triptorelin (Decapeptyl).
    Lindsay PC; Shaw RW; Bennink HJ; Kicovic P
    Fertil Steril; 1996 Feb; 65(2):342-8. PubMed ID: 8566259
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Management of recurrent priapism with epinephrine self-injection and gonadotropin-releasing hormone analogue.
    Steinberg J; Eyre RC
    J Urol; 1995 Jan; 153(1):152-3. PubMed ID: 7966754
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Treatment of endometrial hyperplasia with a danazol-releasing intrauterine device: a prospective study.
    Tamaoka Y; Orikasa H; Sumi Y; Sakakura K; Kamei K; Nagatani M; Ezawa S
    Gynecol Obstet Invest; 2004; 58(1):42-8. PubMed ID: 15087596
    [TBL] [Abstract][Full Text] [Related]  

  • 100. The incidence and characteristics of uterine bleeding during postoperative GnRH agonist treatment combined with tibolone add-back therapy in endometriosis patients of reproductive age.
    Shin SY; Min JA; Yoon BK; Bae DS; Choi DS
    Eur J Obstet Gynecol Reprod Biol; 2007 Jul; 133(1):90-4. PubMed ID: 16806656
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.